| Drug Type AAV based gene therapy | 
| Synonyms adeno-associated virus 8 vector expressing functional human cDNA encoding the N-acetylgalactosamine-6-sulfate sulfatase | 
| Target | 
| Action- | 
| Mechanism GALNS replacements(galactosamine (N-acetyl)-6-sulfatase replacements) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| RegulationOrphan Drug (United States) | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Mucopolysaccharidosis IV | Preclinical | United States  | 20 Sep 2024 | |
| Mucopolysaccharidosis IV | Preclinical | United States  | 20 Sep 2024 | 





